Copyright
©2013 Baishideng Publishing Group Co.
World J Diabetes. Jun 15, 2013; 4(3): 51-63
Published online Jun 15, 2013. doi: 10.4239/wjd.v4.i3.51
Published online Jun 15, 2013. doi: 10.4239/wjd.v4.i3.51
Grade 1: Mild | Symptoms easily controlled |
Regular diet/minor dietary modifications helps to maintain normal nutritional status | |
Grade 2: Compensated | Moderate symptoms that are reasonably controlled with prokinetics and anti-emetics |
Maintenance of nutrition with diet/lifestyle changes | |
Hospitalizations-infrequent | |
Grade 3: Gastric failure | Refractory symptoms |
Inadequate nutrition | |
Needing hospitalization for therapy and nutritional supplementation (either enteral or parenteral) | |
May need surgical or endoscopic intervention or gastric "pacemaker" |
Drug/drug group | Mechanism of action | Common side effects | Efficacy |
Metoclopramide 10 mg 4 times/d | Anti-emetic, reduces nausea and post-prandial fullness, increases gastro-esophageal sphincter tone and improves antro-pyloro-duodenal coordination | Tardive dyskinesia, drowsiness, irritability, extrapyramidal symptoms and dystonic reactions | Symptom control in 1/3 to 2/3 of patients |
Domperidone 10 -20 mg 3 times/d | Similar to metoclopramide with fewer CNS side effects due to a predominant peripheral mechanism of action | May prolong QTc interval in ECG; in turn may provoke cardiac arrhythmia | Effective in up to 60% of cases; tachyphylaxis develops in a few weeks requiring discontinuation |
Erythromycin 50-250 mg thrice daily | Motilin receptor agonist. Reduces gastric emptying time | Nausea and vomiting at high doses | Modest symptom control Intravenous form can be useful in refractory vomiting |
Promethazine, prochlorperazine and chlorpromazine | Mechanism of antiemesis poorly understood | Drowsiness, liver injury and extrapyramidal effects | Marginal improvement of symptoms Intramuscular chlorpromazine is very effective in refractory vomiting |
Ondansetron | Central serotonin receptor (5-HT3) antagonist Inhibits vagus nerve | Extrapyramidal effect | Modest efficacy |
- Citation: Krishnan B, Babu S, Walker J, Walker AB, Pappachan JM. Gastrointestinal complications of diabetes mellitus. World J Diabetes 2013; 4(3): 51-63
- URL: https://www.wjgnet.com/1948-9358/full/v4/i3/51.htm
- DOI: https://dx.doi.org/10.4239/wjd.v4.i3.51